Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Verrica is set to report Q1 2026 results on May 12 before the market, with analysts forecasting a ($0.59) loss per share and about $4.51 million in revenue; the earnings call is scheduled for 4:30 PM ET.
• Last quarter the company reported a ($0.51) EPS miss versus estimates while posting $5.09 million in revenue, and shares recently traded up 8.6% to $6.91 as the company has a market cap of $118.6M and a negative P/E (‑4.37).
• Analyst sentiment is mixed-to-negative with a MarketBeat consensus rating of "Reduce" (one Buy, one Hold, two Sells) and an average price target of $17, while institutional investors own about 42.45% of the stock.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $4.5140 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its earnings results on Wednesday, March 11th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). The firm had revenue of $5.09 million for the quarter, compared to analysts' expectations of $4.52 million. On average, analysts expect Verrica Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Trading Up 8.6%

Shares of VRCA traded up $0.55 during trading hours on Tuesday, reaching $6.91. 24,288 shares of the company traded hands, compared to its average volume of 124,469. The company's fifty day moving average price is $5.72 and its two-hundred day moving average price is $6.13. The company has a market capitalization of $118.64 million, a price-to-earnings ratio of -4.37 and a beta of 1.54. The company has a quick ratio of 2.45, a current ratio of 2.59 and a debt-to-equity ratio of 0.03. Verrica Pharmaceuticals has a 12 month low of $3.28 and a 12 month high of $9.82.

Analyst Ratings Changes

A number of research analysts recently issued reports on VRCA shares. Zacks Research cut shares of Verrica Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday, April 7th. Wall Street Zen cut shares of Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, February 7th. Finally, TD Cowen reiterated a "buy" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, January 7th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Reduce" and an average price target of $17.00.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several hedge funds have recently modified their holdings of VRCA. State Street Corp raised its stake in Verrica Pharmaceuticals by 14.1% during the fourth quarter. State Street Corp now owns 23,481 shares of the company's stock valued at $195,000 after purchasing an additional 2,900 shares in the last quarter. Man Group plc purchased a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at $94,000. Quadrature Capital Ltd purchased a new position in Verrica Pharmaceuticals in the 4th quarter worth about $99,000. Beck Mack & Oliver LLC purchased a new position in Verrica Pharmaceuticals in the 4th quarter worth about $100,000. Finally, Bridgeway Capital Management LLC purchased a new position in Verrica Pharmaceuticals in the 3rd quarter worth about $52,000. Hedge funds and other institutional investors own 42.45% of the company's stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica's approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.